413 related articles for article (PubMed ID: 9513720)
1. Use of mouse mammary tumour virus (MMTV)/neu transgenic mice to identify genes collaborating with the c-erbB-2 oncogene in mammary tumour development.
Jolicoeur P; Bouchard L; Guimond A; Ste-Marie M; Hanna Z; Dievart A
Biochem Soc Symp; 1998; 63():159-65. PubMed ID: 9513720
[TBL] [Abstract][Full Text] [Related]
2. p130Cas as a new regulator of mammary epithelial cell proliferation, survival, and HER2-neu oncogene-dependent breast tumorigenesis.
Cabodi S; Tinnirello A; Di Stefano P; Bisarò B; Ambrosino E; Castellano I; Sapino A; Arisio R; Cavallo F; Forni G; Glukhova M; Silengo L; Altruda F; Turco E; Tarone G; Defilippi P
Cancer Res; 2006 May; 66(9):4672-80. PubMed ID: 16651418
[TBL] [Abstract][Full Text] [Related]
3. MMTV promoter hypomethylation is linked to spontaneous and MNU associated c-neu expression and mammary carcinogenesis in MMTV c-neu transgenic mice.
Zhou H; Chen WD; Qin X; Lee K; Liu L; Markowitz SD; Gerson SL
Oncogene; 2001 Sep; 20(42):6009-17. PubMed ID: 11593408
[TBL] [Abstract][Full Text] [Related]
4. In vitro and in vivo antisense-mediated growth inhibition of a mammary adenocarcinoma from MMTV-neu transgenic mice.
Sacco MG; Barbieri O; Piccini D; Noviello E; Zoppé M; Zucchi I; Frattini A; Villa A; Vezzoni P
Gene Ther; 1998 Mar; 5(3):388-93. PubMed ID: 9614559
[TBL] [Abstract][Full Text] [Related]
5. Rassf3 is responsible in part for resistance to mammary tumor development in neu transgenic mice.
Jacquemart IC; Springs AE; Chen WY
Int J Oncol; 2009 Feb; 34(2):517-28. PubMed ID: 19148488
[TBL] [Abstract][Full Text] [Related]
6. Identification of tumorsphere- and tumor-initiating cells in HER2/Neu-induced mammary tumors.
Liu JC; Deng T; Lehal RS; Kim J; Zacksenhaus E
Cancer Res; 2007 Sep; 67(18):8671-81. PubMed ID: 17875707
[TBL] [Abstract][Full Text] [Related]
7. The matrix metalloproteinase matrilysin influences early-stage mammary tumorigenesis.
Rudolph-Owen LA; Chan R; Muller WJ; Matrisian LM
Cancer Res; 1998 Dec; 58(23):5500-6. PubMed ID: 9850086
[TBL] [Abstract][Full Text] [Related]
8. Induction of a variety of preneoplasias and tumours in the mammary glands of transgenic rats.
Davies BR; Warren JR; Schmidt G; Rudland PS
Biochem Soc Symp; 1998; 63():167-84. PubMed ID: 9513721
[TBL] [Abstract][Full Text] [Related]
9. Lack of ductal development in the absence of functional estrogen receptor alpha delays mammary tumor formation induced by transgenic expression of ErbB2/neu.
Hewitt SC; Bocchinfuso WP; Zhai J; Harrell C; Koonce L; Clark J; Myers P; Korach KS
Cancer Res; 2002 May; 62(10):2798-805. PubMed ID: 12019156
[TBL] [Abstract][Full Text] [Related]
10. Cooperating oncogenic events in murine mammary tumorigenesis: assessment of ErbB2, mutant p53, and mouse mammary tumor virus.
Zelazny E; Li B; Anagnostopoulos AM; Coleman A; Perkins AS
Exp Mol Pathol; 2001 Jun; 70(3):183-93. PubMed ID: 11417997
[TBL] [Abstract][Full Text] [Related]
11. Somatic mutations that contribute to breast cancer.
Callahan R
Biochem Soc Symp; 1998; 63():211-21. PubMed ID: 9513725
[TBL] [Abstract][Full Text] [Related]
12. Involvement of Notch1 in the development of mouse mammary tumors.
Diévart A; Beaulieu N; Jolicoeur P
Oncogene; 1999 Oct; 18(44):5973-81. PubMed ID: 10557086
[TBL] [Abstract][Full Text] [Related]
13. Challenge with mammary tumor cells expressing MHC class II and CD80 prevents the development of spontaneously arising tumors in MMTV-neu transgenic mice.
Jabrane-Ferrat N; Campbell MJ; Esserman LJ; Peterlin BM
Cancer Gene Ther; 2006 Nov; 13(11):1002-10. PubMed ID: 16841083
[TBL] [Abstract][Full Text] [Related]
14. Transgenic mice with mammary gland targeted expression of human cortactin do not develop (pre-malignant) breast tumors: studies in MMTV-cortactin and MMTV-cortactin/-cyclin D1 bitransgenic mice.
van Rossum AG; van Bragt MP; Schuuring-Scholtes E; van der Ploeg JC; van Krieken JH; Kluin PM; Schuuring E
BMC Cancer; 2006 Mar; 6():58. PubMed ID: 16536875
[TBL] [Abstract][Full Text] [Related]
15. Induction of epithelial abnormalities that resemble human breast lesions by the expression of the neu/erbB-2 oncogene in reconstituted mouse mammary gland.
Bradbury JM; Arno J; Edwards PA
Oncogene; 1993 Jun; 8(6):1551-8. PubMed ID: 8099220
[TBL] [Abstract][Full Text] [Related]
16. Celecoxib, a selective cyclooxygenase 2 inhibitor, protects against human epidermal growth factor receptor 2 (HER-2)/neu-induced breast cancer.
Howe LR; Subbaramaiah K; Patel J; Masferrer JL; Deora A; Hudis C; Thaler HT; Muller WJ; Du B; Brown AM; Dannenberg AJ
Cancer Res; 2002 Oct; 62(19):5405-7. PubMed ID: 12359744
[TBL] [Abstract][Full Text] [Related]
17. Maspin expression inversely correlates with breast tumor progression in MMTV/TGF-alpha transgenic mouse model.
Reddy KB; McGowen R; Schuger L; Visscher D; Sheng S
Oncogene; 2001 Oct; 20(45):6538-43. PubMed ID: 11641778
[TBL] [Abstract][Full Text] [Related]
18. Mouse mammary tumor virus p75 and p110 CUX1 transgenic mice develop mammary tumors of various histologic types.
Cadieux C; Kedinger V; Yao L; Vadnais C; Drossos M; Paquet M; Nepveu A
Cancer Res; 2009 Sep; 69(18):7188-97. PubMed ID: 19738070
[TBL] [Abstract][Full Text] [Related]
19. Fgf10 is an oncogene activated by MMTV insertional mutagenesis in mouse mammary tumors and overexpressed in a subset of human breast carcinomas.
Theodorou V; Boer M; Weigelt B; Jonkers J; van der Valk M; Hilkens J
Oncogene; 2004 Aug; 23(36):6047-55. PubMed ID: 15208658
[TBL] [Abstract][Full Text] [Related]
20. Tamoxifen chemoprevention of a hormone-independent tumor in the proto-neu transgenic mice model.
Ménard S; Aiello P; Tagliabue E; Rumio C; Lollini PL; Colnaghi MI; Balsari A
Cancer Res; 2000 Jan; 60(2):273-5. PubMed ID: 10667575
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
